筋層非浸潤性膀胱癌に対する尿アルカリ化療法併用によるマイトマイシン膀胱内注入療法の治療経験

Clinical outcome of intravesical instillation by mitomycin C with urine alkalinization for non-muscle invasive bladder cancer

　マイトマイシン膀胱内注入療法の有効性に影響を与える因子の1つに尿pHが指摘されている．今回，非筋層浸潤性膀胱癌21例に対して尿アルカリ化療法併用マイトマイシンC膀胱内注入療法を施行した．尿pHはウラリット併用にて平均で治療前の6.1から6.7へと上昇していた．13例（61.9％）に有害事象があったが，すべてがGradeⅠであった．1年および3年非再発率は，それぞれ95.2％，85.7％であった．疾患特異的5年生存率は100％であった．当治療は安全であり，治療成績も他の報告同様に良好であった．

Abstract

Urinary pH is a factor which affectes the efficacy of intravesical instillation by mitomycin C (MMC). Intravesical instillation by MMC with urine alkalinization was performed in 21 cases of non-muscle invasive bladder cancer. The average urinary pH increased from 6.1 by Uralyt^® administration to 6.7. An adverse event was noted in 13 cases (61.9%), but all cases were Grade 1. The 1- and 3-year non-recurrence rates were 95.2% and 85.7%, respectively. The disease-specific 5-year survival rate was 100%. This study was safe, and the treatment outcome was good, which was consistent with the results of other previous reports (Rinsho Hinyokika 71 : 833-837, 2017).